1] Inserm U1149, Centre de Recherche sur l'Inflammation (CRI), Paris, France [2] UMR_S 1149, Faculté de Médecine, Université Paris-Diderot, Paris 7, Paris, France [3] Département Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France [4] Laboratoire d'Excellence (Labex) Inflamex, PRES Sorbonne Paris Cité, Paris, France.
1] Département Hospitalo-Universitaire (DHU) UNITY, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Clichy, France [2] Inserm U970, Paris Cardiovascular Research Center-PARCC, Paris, France [3] UMR-S970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Am J Gastroenterol. 2014 Sep;109(9):1424-6. doi: 10.1038/ajg.2014.250.
Severe alcoholic hepatitis is a life-threatening liver disease. Although corticosteroid treatment is recommended and improves survival, mortality remains high and 35% of patients die within 6 months. There is no available medical treatment for patients who do not respond to corticosteroids. A new randomized pilot trial shows that the administration of the cytokine granulocyte colony-stimulating factor (G-CSF) improves liver function and 3-month survival in patients with severe alcoholic hepatitis. These results suggest a new therapeutic approach for severe alcoholic hepatitis.
严重酒精性肝炎是一种危及生命的肝脏疾病。虽然皮质类固醇治疗被推荐并能提高生存率，但死亡率仍然很高，35%的患者在 6 个月内死亡。对于那些对皮质类固醇治疗无反应的患者，尚无可用的医疗方法。一项新的随机试验表明，细胞因子粒细胞集落刺激因子（G-CSF）的给药可改善严重酒精性肝炎患者的肝功能和 3 个月生存率。这些结果为严重酒精性肝炎提供了一种新的治疗方法。
